The survival analysis showed that CHOL, KIRP, and SARC patients with low expression levels of ANGPTL3 had a shorter survival time, whereas KICH, LAML, and LIHC cancer patients with low expression levels of ANGPTL3 exhibited a high survival rate (Figure 5b,d,e). Here, ANGPTL3 is linked to cancer.